Haematologica (Apr 2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
- Nicola Gökbuget,
- Gerhard Zugmaier,
- Matthias Klinger,
- Peter Kufer,
- Matthias Stelljes,
- Andreas Viardot,
- Heinz A. Horst,
- Svenja Neumann,
- Monika Brüggemann,
- Oliver G. Ottmann,
- Thomas Burmeister,
- Dorothea Wessiepe,
- Max S. Topp,
- Ralf Bargou
Affiliations
- Nicola Gökbuget
- Center of Internal Medicine, Goethe University, Frankfurt, Germany
- Gerhard Zugmaier
- Amgen Research (Munich) GmbH, Germany
- Matthias Klinger
- Amgen Research (Munich) GmbH, Germany
- Peter Kufer
- Amgen Research (Munich) GmbH, Germany
- Matthias Stelljes
- Medical Department A, University of Münster, Germany
- Andreas Viardot
- Department for Internal Medicine III, University Ulm, Germany
- Heinz A. Horst
- Medical Department II, Christian-Albrechts University, Kiel, Germany
- Svenja Neumann
- Medical Department II, Christian-Albrechts University, Kiel, Germany
- Monika Brüggemann
- Medical Department II, Christian-Albrechts University, Kiel, Germany
- Oliver G. Ottmann
- Department of Haematology, Cardiff University, Cardiff, UK
- Thomas Burmeister
- Department for Hematology and Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
- Dorothea Wessiepe
- Metronomia Clinical Research GmbH, München, Germany
- Max S. Topp
- Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany
- Ralf Bargou
- Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany
- DOI
- https://doi.org/10.3324/haematol.2016.153957
- Journal volume & issue
-
Vol. 102,
no. 4
Abstract
No abstracts available.